CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
On September 14, 2020, our Phoenix laboratory began performing a portion of our alternate donor anti...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
We have now added a new section called the "Assay History List" to the "At A Gla...
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm. Th...
Currently, there are limited supplies of the reagents used for HIV-1 Western Blot and HIV-2 EIA test...
As communicated on January 21, 2020, CTS will implement the licensed Grifols Babesia test for sample...